No price history available.
Key financial summary
Financials in USD| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM | 2026E | ||
|---|---|---|---|---|---|---|---|---|---|
| Total revenue | $m | 1 | 2 | 2 | 1 | 3 | 3 | N/A | N/A |
| Operating profit | $m | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Net profit | $m | 0 | 0 | -0 | -0 | 0 | -0 | N/A | N/A |
| EPS reported | $ | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Operating cashflow per share | $ | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Capex per share | $ | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| FCF per share | $ | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Free cash flow | $m | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Net debt | $m | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Book value equity | $m | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Book value per share | $ | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Number of shares | m | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| DPS (TTM paid) | $ | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
Financial summary
Financials in USD| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM | 2026E | ||
|---|---|---|---|---|---|---|---|---|---|
| Value | |||||||||
| P/E LTM | x | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| P/B LTM | x | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| P/S LTM | x | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| P/FCF LTM | x | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| EV/EBITDA LTM | x | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| EV/Sales LTM | x | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Earnings Yield LTM | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| FCF Yield | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Quality | |||||||||
| ROE | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| ROIC | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Operating margin | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Gross margin | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| FCF/Sales | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Growth and momentum | |||||||||
| EPS Growth YoY | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Sales Growth YoY | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Net Income Growth YoY | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| FCF Growth | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Operating Profit Growth | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Dividend and capital structure | |||||||||
| Dividend Yield | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Dividend Growth | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Payout Ratio | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| FCF/Debt | x | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Net Debt/EBITDA | x | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| EBIT/Net interest | x | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Net debt/market cap | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Net debt/Equity | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Gross debt/equity | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
Price target estimates
Based on consensus from external analysts. Not Kvantra's opinion.
Ratings
Based on consensus from external analysts. Not Kvantra's opinion.
ESG
| Metric | 2024 | 2025 | 2026 |
|---|---|---|---|
| ESG-score | Locked | Locked | Locked |
| Environmental score | Locked | Locked | Locked |
| Social score | Locked | Locked | Locked |
| Governance score | Locked | Locked | Locked |
| Risk rating | Locked | Locked | Locked |
Company overview
DSwiss, Inc. is a biotech-nutraceutical company that supplies a comprehensive range of health and beauty products. Its market reach extends across Malaysia, Singapore, Indonesia, Taiwan, Macau, Hong Kong, and China. The company's product line includes specialized items like DSwiss coffee, targeting digestive well-being, and DSwiss kiwi, formulated to boost the immune system, improve skin tone, help manage blood pressure, and minimize the risk of heart disease and stroke. DSwiss Triple SC focuses on stem cell-related benefits. For skincare, DSwiss offers the DSwiss silk mask, designed for dry, damaged, and sensitive skin; the DSwiss coffee slimming scrub, a natural body exfoliant for removing impurities; the cooling DSwiss peppermint slimming gel; the DSwiss new age essence, which provides nutrients to moisturize, brighten, and refresh tired-looking skin; and the DSwiss enlighten essence cream, a light, nourishing formula. DSwiss also provides medical eyewear under the name DSwiss BioSpec. Its broader health offerings include Genmune-Pro, which strengthens the human immune system by enhancing digestive health; SkinEra, a solution for various skin conditions such as acne, pimples, atopic dermatitis, dry skin, and allergic rashes; SensiBath gel; and SuiSu hand purifiers, sanitizers, and air sanitizers. Specialized supplements include MasterLiv for liver support, MasterHeart for maintaining optimal heart health and smooth blood circulation, and WellG, which delivers essential nutrients for sugar metabolism and energy production. In addition to its product range, DSwiss, Inc. offers diagnostic and analytical equipment. This includes the DSwiss quantum magnetic analyzer, a device that interprets body energy fields to assess health status and offer recommendations, and an AI skin analyzer machine, a facial camera designed to collect skin image data. The company also provides turnkey private label manufacturing services and DNA microarray genotyping services. Furthermore, DSwiss supplies a variety of medical consumables, such as surgical gowns and gloves, 3-ply face masks, N95 masks, protective goggles, body infrared thermometers, disposable bedsheets, and stretcher covers. DSwiss, Inc. was incorporated in 2015 and is headquartered in Kuala Lumpur, Malaysia.
Similar companies
For informational purposes only. Kvantra provides data and quantitative analysis, not investment advice. KvantraRank is a mechanical model output. Analyst price targets and ratings are sourced from third parties and are not Kvantra recommendations. Past performance does not guarantee future results; all investments carry risk.
No price history available.
Not enough data to calculate KvantraRank
Consensus from external analysts. Not Kvantra's opinion.
Based on consensus from external analysts. Not Kvantra's opinion.
DSwiss, Inc. is a biotech-nutraceutical company that supplies a comprehensive range of health and beauty products. Its market reach extends across Malaysia, Singapore, Indonesia, Taiwan, Macau, Hong Kong, and China. The company's product line includes specialized items like DSwiss coffee, targeting digestive well-being, and DSwiss kiwi, formulated to boost the immune system, improve skin tone, help manage blood pressure, and minimize the risk of heart disease and stroke. DSwiss Triple SC focuses on stem cell-related benefits. For skincare, DSwiss offers the DSwiss silk mask, designed for dry, damaged, and sensitive skin; the DSwiss coffee slimming scrub, a natural body exfoliant for removing impurities; the cooling DSwiss peppermint slimming gel; the DSwiss new age essence, which provides nutrients to moisturize, brighten, and refresh tired-looking skin; and the DSwiss enlighten essence cream, a light, nourishing formula. DSwiss also provides medical eyewear under the name DSwiss BioSpec. Its broader health offerings include Genmune-Pro, which strengthens the human immune system by enhancing digestive health; SkinEra, a solution for various skin conditions such as acne, pimples, atopic dermatitis, dry skin, and allergic rashes; SensiBath gel; and SuiSu hand purifiers, sanitizers, and air sanitizers. Specialized supplements include MasterLiv for liver support, MasterHeart for maintaining optimal heart health and smooth blood circulation, and WellG, which delivers essential nutrients for sugar metabolism and energy production. In addition to its product range, DSwiss, Inc. offers diagnostic and analytical equipment. This includes the DSwiss quantum magnetic analyzer, a device that interprets body energy fields to assess health status and offer recommendations, and an AI skin analyzer machine, a facial camera designed to collect skin image data. The company also provides turnkey private label manufacturing services and DNA microarray genotyping services. Furthermore, DSwiss supplies a variety of medical consumables, such as surgical gowns and gloves, 3-ply face masks, N95 masks, protective goggles, body infrared thermometers, disposable bedsheets, and stretcher covers. DSwiss, Inc. was incorporated in 2015 and is headquartered in Kuala Lumpur, Malaysia.